These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19009280)

  • 1. Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp).
    Dreux M; Cosset FL
    Methods Mol Biol; 2009; 510():427-38. PubMed ID: 19009280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
    Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
    Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).
    Berger A; Giroglou T; Leutz A; Ogbomo H; Pfaff K; Teuber G; Cinatl J; van Laer D; Doerr HW
    J Clin Virol; 2009 Sep; 46(1):55-60. PubMed ID: 19560398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studying HCV cell entry with HCV pseudoparticles (HCVpp).
    Bartosch B; Cosset FL
    Methods Mol Biol; 2009; 510():279-93. PubMed ID: 19009269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
    Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
    Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
    Wasilewski LN; Ray SC; Bailey JR
    J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for the study of hepatitis C virus entry.
    Castet V; Moradpour D
    Hepatology; 2003 Sep; 38(3):771-4. PubMed ID: 12939604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.
    Meunier JC; Engle RE; Faulk K; Zhao M; Bartosch B; Alter H; Emerson SU; Cosset FL; Purcell RH; Bukh J
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4560-5. PubMed ID: 15767578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
    Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
    Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
    Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
    Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
    Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.
    von Hahn T; Yoon JC; Alter H; Rice CM; Rehermann B; Balfe P; McKeating JA
    Gastroenterology; 2007 Feb; 132(2):667-78. PubMed ID: 17258731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
    Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
    J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.
    Helle F; Vieyres G; Elkrief L; Popescu CI; Wychowski C; Descamps V; Castelain S; Roingeard P; Duverlie G; Dubuisson J
    J Virol; 2010 Nov; 84(22):11905-15. PubMed ID: 20844034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.